Stay updated on Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.

Latest updates to the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedStudy design, interventions, outcomes, eligibility criteria, and dates appear unchanged compared with the previous version. No new content or deletions affecting the core information on the Study Details page were detected.SummaryDifference0.3%

- Check20 days agoNo Change Detected
- Check42 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference1%

- Check49 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

- Check63 days agoChange DetectedUpdated the page from Revision: v3.0.1 to Revision: v3.0.2. The 'Back to Top' element was removed, a minor UI change.SummaryDifference0.1%

- Check70 days agoChange DetectedThe page has updated the publication date and version number of a study on tildrakizumab's efficacy and safety in psoriasis patients.SummaryDifference0.2%

- Check78 days agoChange DetectedThe web page has been updated to include new drug information for Tildrakizumab and a new facility name and location, while removing several previous location details and drug information for Etanercept.SummaryDifference3%

Stay in the know with updates to Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tildrakizumab for Chronic Plaque Psoriasis Clinical Trial page.